Zai Lab (ZLAB) Partner Novocure (NVCR) Announces METIS Phase 3 Clinical Trial Met Primary Endpoint

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/29/2026

1. V
2. KLAC
3. F
4. STX
5. PYPL
6. BE
7. SWKS
8. CSGP
9. VRNS
10. ENPH

Go back to Zai Lab (ZLAB) Partner Novocure (NVCR) Announces METIS Phase 3 Clinical Trial Met Primary Endpoint

Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Me

March 27, 2024 9:29 AM EDT

The METIS trial demonstrated 21.9 months median time to intracranial progression for patients treated with Tumor Treating Fields and supportive care compared to 11.3 months for patients treated with supportive care alone

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) partner Novocure (NASDAQ: NVCR) today announced the phase 3 METIS clinical trial met its primary endpoint, demonstrating a statistically significant improvement in time to intracranial progression for adult patients treated with Tumor Treating Fields (TTFields) therapy and supportive care compared to... More